Sarepta Therapeutics, Inc. (SRPT) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: 52.21
30Y Low52.2·High52.2
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
1.91
↓-84% vs avg
5yr avg: 11.66
30Y Low2.0·High29.5
ROE
↓
-53.5%
↓+3% vs avg
5yr avg: -55.3%
30Y Low-309%·High20%
Debt/EBITDA
N/A
—
5yr avg: 5.25
30Y Low5.3·High5.3
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
SRPT Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Sarepta Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.2B | $2.3B | $13.1B | $8.9B | $11.3B | $7.3B | $13.3B | $9.5B | $7.2B | $3.3B | $1.3B |
| Enterprise Value | $2.4B | $2.5B | $13.4B | $9.9B | $12.0B | $6.4B | $12.9B | $9.4B | $7.3B | $3.1B | $1.2B |
| P/E Ratio → | -2.92 | — | 51.96 | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.99 | 1.03 | 6.90 | 7.17 | 12.16 | 10.43 | 24.61 | 24.94 | 24.02 | 21.17 | 246.40 |
| P/B Ratio | 1.91 | 1.98 | 8.59 | 10.37 | 29.47 | 7.89 | 17.45 | 11.61 | 7.00 | 4.15 | 3.97 |
| P/FCF | — | — | — | — | — | — | 526.07 | — | — | — | — |
| P/OCF | — | — | — | — | — | — | 123.67 | — | — | — | — |
P/E links to full P/E history page with 30-year chart
SRPT EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.13 | 7.02 | 7.95 | 12.86 | 9.05 | 23.85 | 24.69 | 24.18 | 20.08 | 226.80 |
| EV / EBITDA | — | — | 52.21 | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | 47.84 | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | 509.89 | — | — | — | — |
SRPT Profitability
Margins and return-on-capital ratios measuring operating efficiency
Sarepta Therapeutics, Inc. earns an operating margin of -29.9%. Operating margins have compressed from -21.5% to -29.9% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -53.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 59.9% | 59.9% | 83.2% | 87.9% | 85.0% | 86.2% | 88.3% | 85.1% | 88.6% | 95.2% | 97.6% |
| Operating Margin | -29.9% | -29.9% | 11.5% | -21.5% | -57.5% | -65.5% | -104.5% | -185.3% | -114.1% | -111.0% | -4920.3% |
| Net Profit Margin | -32.5% | -32.5% | 12.4% | -43.1% | -75.4% | -59.7% | -102.6% | -187.8% | -120.2% | -32.8% | -4930.2% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -53.5% | -53.5% | 19.7% | -86.2% | -107.2% | -49.6% | -70.1% | -77.3% | -39.7% | -9.0% | -101.4% |
| ROA | -19.5% | -19.5% | 6.5% | -16.8% | -22.4% | -13.7% | -23.1% | -41.3% | -24.5% | -5.9% | -76.6% |
| ROIC | -31.4% | -31.4% | 9.1% | -14.0% | -80.3% | -216.5% | -78.8% | -58.7% | -30.3% | -30.3% | -110.0% |
| ROCE | -24.0% | -24.0% | 7.5% | -10.5% | -20.6% | -17.5% | -27.3% | -46.6% | -25.6% | -21.9% | -95.2% |
SRPT Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $238M ($1.0B total debt minus $801M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.91 | 0.91 | 0.88 | 1.63 | 4.20 | 1.24 | 1.44 | 0.90 | 0.41 | 0.55 | 0.05 |
| Debt / EBITDA | — | — | 5.25 | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.21 | 0.16 | 1.13 | 1.69 | -1.04 | -0.54 | -0.12 | 0.05 | -0.21 | -0.32 |
| Net Debt / EBITDA | — | — | 0.94 | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | -16.18 | — | — | — | — |
| Interest Coverage | -71.16 | -71.16 | 15.18 | -22.63 | -11.96 | -5.60 | -8.23 | -22.28 | -9.76 | -7.41 | -140.98 |
SRPT Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Sarepta Therapeutics, Inc.'s current ratio of 2.32x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 1.48x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 3.95x to 2.32x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.32 | 2.32 | 4.20 | 3.95 | 4.13 | 5.75 | 5.97 | 5.55 | 8.21 | 13.91 | 4.95 |
| Quick Ratio | 1.48 | 1.48 | 3.18 | 3.45 | 3.80 | 5.34 | 5.42 | 4.90 | 7.49 | 12.96 | 4.78 |
| Cash Ratio | 0.86 | 0.86 | 1.85 | 2.56 | 3.21 | 4.67 | 4.66 | 4.25 | 6.76 | 12.22 | 4.21 |
| Asset Turnover | — | 0.66 | 0.48 | 0.38 | 0.30 | 0.22 | 0.18 | 0.21 | 0.18 | 0.12 | 0.01 |
| Inventory Turnover | 0.96 | 0.96 | 0.43 | 0.47 | 0.69 | 0.52 | 0.27 | 0.33 | 0.27 | 0.09 | 0.01 |
| Days Sales Outstanding | — | 66.12 | 124.69 | 128.28 | 102.34 | 89.83 | 93.65 | 90.03 | 59.47 | 69.58 | 352.01 |
SRPT Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Sarepta Therapeutics, Inc. returns 1.1% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 1.9% | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | 0.2% | — | — | — | — |
| Buyback Yield | 1.1% | 1.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 1.1% | 1.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $105M | $108M | $92M | $88M | $81M | $78M | $74M | $66M | $59M | $49M |
Peer Comparison
Compare SRPT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 SRPTYou | $2B | -2.9 | — | — | 59.9% | -29.9% | -53.5% | -31.4% | — |
 BMRN | $10B | 30.1 | 15.9 | 14.4 | 77.1% | 16.6% | 5.9% | 7.4% | 1.0 |
 ALNY | $39B | 127.0 | 70.2 | 84.8 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 RARE | $3B | -4.5 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 IONS | $13B | -31.9 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 KRYS | $9B | 43.4 | 49.2 | 46.3 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 CRSP | $5B | -8.1 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 EDIT | $297M | -1.7 | — | — | — | — | -198.1% | — | — |
 NTLA | $2B | -3.6 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 SGMO | $22M | -0.2 | — | — | 100.0% | -179.9% | -185.4% | -178.8% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
See SRPT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SRPT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SRPT vs BMRN
Side-by-side business, growth, and profitability comparison vs BioMarin Pharmaceutical Inc..
Start ComparisonSRPT — Frequently Asked Questions
Quick answers to the most common questions about buying SRPT stock.
What is Sarepta Therapeutics, Inc.'s P/E ratio?
Sarepta Therapeutics, Inc.'s current P/E ratio is -2.9x. The historical average is 52.0x.
What is Sarepta Therapeutics, Inc.'s ROE?
Sarepta Therapeutics, Inc.'s return on equity (ROE) is -53.5%. The historical average is -83.8%.
Is SRPT stock overvalued?
Based on historical data, Sarepta Therapeutics, Inc. is trading at a P/E of -2.9x. Compare with industry peers and growth rates for a complete picture.
What are Sarepta Therapeutics, Inc.'s profit margins?
Sarepta Therapeutics, Inc. has 59.9% gross margin and -29.9% operating margin.